Blinatumomab: A historical perspective

Pharmacology and Therapeutics

Volumn 136, Issue 3, 2012, Pages 334-342

  Nagorsen, Dirk ^a   Kufer, Peter ^a   Baeuerle, Patrick A ^a   Bargou, Ralf ^b  

^a Amgen Research GmbH   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Bispecific antibody; BiTE ; Leukemia; Lymphoma

Indexed keywords

AMG 103; BLINATUMOMAB; CD19 ANTIGEN; DEXAMETHASONE; GAMMA GLUTAMYLTRANSFERASE; MEDI 565; MONOCLONAL ANTIBODY; MT 110; MT 111; MUS 103; MUS103; RITUXIMAB; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADENOCARCINOMA; ANTIGEN EXPRESSION; APHASIA; ATAXIA; BRAIN DISEASE; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER REGRESSION; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM DISEASE; CHILL; CHROMOSOME TRANSLOCATION; CHRONIC LYMPHATIC LEUKEMIA; CONTINUOUS INFUSION; CONVULSION; CYTOKINE RELEASE SYNDROME; DISORIENTATION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FATIGUE; FOLLICULAR LYMPHOMA; HUMAN; HYPERGLYCEMIA; IN VITRO STUDY; LARGE CELL LYMPHOMA; LEUKOPENIA; LYMPHOCYTOPENIA; MANTLE CELL LYMPHOMA; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RIGOR; SEIZURE; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; TUMOR ASSOCIATED LEUKOCYTE; WEIGHT CHANGE;

ANIMALS; ANTIBODIES, BISPECIFIC; CLINICAL TRIALS AS TOPIC; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, MANTLE-CELL; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84867858547     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2012.07.013     Document Type: Review

References (51)

1. P.A. Baeuerle, and C. Itin Clinical experience with gene therapy and bispecific antibodies for T cell-based therapy of cancer Curr Pharm Biotechnol 13 2012 1399 1408
2. P.A. Baeuerle, P. Kufer, and R. Bargou BiTE: Teaching antibodies to engage T-cells for cancer therapy Curr Opin Mol Ther 11 2009 22 30
3. P.A. Baeuerle, and C. Reinhardt Bispecific T-cell engaging antibodies for cancer therapy Cancer Res 69 2009 4941 4944
4. P.A. Baeuerle, G. Zugmaier, and D. Rüttinger Bispecific T cell engager for cancer therapy R. Kontermann, Bispecific antibodies 2011 273 287
5. G.V. Baracho, A.V. Miletic, S.A. Omori, M.H. Cato, and R.C. Rickert Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation Curr Opin Immunol 23 2011 178 183
6. R. Bargou, E. Leo, G. Zugmaier, M. Klinger, M. Goebeler, and S. Knop Tumor regression in cancer patients by very low doses of a T cell-engaging antibody Science 321 2008 974 977
7. R. Bassan, O. Spinelli, E. Oldani, T. Intermesoli, M. Tosi, and B. Peruta Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL) Blood 113 2009 4153 4162
8. C. Brandl, C. Haas, S. d'Argouges, T. Fisch, P. Kufer, and K. Brischwein The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct Cancer Immunol Immunother 56 2007 1551 1563
9. I.H. Brinkman, M.A. van de Laar, T.L. Jansen, and E.N. van Roon The potential risk of infections during (prolonged) rituximab therapy in rheumatoid arthritis Expert Opin Drug Saf 10 2011 715 726
10. K. Brischwein, L. Parr, S. Pflanz, J. Volkland, J. Lumsden, and M. Klinger Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class J Immunother 30 2007 798 807
11. S. d'Argouges, S. Wissing, C. Brandl, N. Prang, R. Lutterbuese, and A. Kozhich Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells Leuk Res 33 2009 465 473
12. T. Dreier, P.A. Baeuerle, I. Fichtner, M. Grun, B. Schlereth, and G. Lorenczewski T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct J Immunol 170 2003 4397 4402
13. T. Dreier, G. Lorenczewski, C. Brandl, P. Hoffmann, U. Syring, and F. Hanakam Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody Int J Cancer 100 2002 690 697
14. S. Ferrone, and T.L. Whiteside Tumor microenvironment and immune escape Surg Oncol Clin N Am 16 2007 755 774 (viii)
15. M. Fujimoto, J.C. Poe, M. Inaoki, and T.F. Tedder CD19 regulates B lymphocyte responses to transmembrane signals Semin Immunol 10 1998 267 277
16. J. Galon, A. Costes, F. Sanchez-Cabo, A. Kirilovsky, B. Mlecnik, and C. Lagorce-Pages Type, density, and location of immune cells within human colorectal tumors predict clinical outcome Science 313 2006 1960 1964
17. M. Goebeler, A. Viardot, R. Noppeney, S. Krause, A. Mackensen, and K. Rupertus Blinatumomab (CD3/CD19 BiTE antibody) results in a high response rate in patients with relapsed non-Hodgkin lymphoma (NHL) including MCL and DLBCL Ann Oncol 22 Suppl. 4 2011 iv104 iv105
18. M. Gruen, K. Bommert, and R.C. Bargou T-cell-mediated lysis of B cells induced by a CD19 × CD3 bispecific single-chain antibody is perforin dependent and death receptor independent Cancer Immunol Immunother 53 2004 625 632
19. C. Haas, E. Krinner, K. Brischwein, P. Hoffmann, R. Lutterbuse, and B. Schlereth Mode of cytotoxic action of T cell-engaging BiTE antibody MT110 Immunobiology 214 2009 441 453
20. R. Handgretinger, G. Zugmaier, G. Henze, H. Kreyenberg, P. Lang, and A. von Stackelberg Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia Leukemia 25 2011 181 184
21. P. Hoffmann, R. Hofmeister, K. Brischwein, C. Brandl, S. Crommer, and R. Bargou Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct Int J Cancer 115 2005 98 104
22. C.A. Hurwitz, M.R. Loken, M.L. Graham, J.E. Karp, M.J. Borowitz, and D.J. Pullen Asynchronous antigen expression in B lineage acute lymphoblastic leukemia Blood 72 1988 299 307
23. M. Kalos, B.L. Levine, D.L. Porter, S. Katz, S.A. Grupp, and A. Bagg T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia Sci Transl Med 3 2011 95ra73
24. P. Kischel, F. Guillonneau, B. Dumont, A. Bellahcene, V. Stresing, and P. Clezardin Cell membrane proteomic analysis identifies proteins differentially expressed in osteotropic human breast cancer cells Neoplasia 10 2008 1014 1020
25. + cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL Leukemia 22 2008 1207 1213
26. P. Kufer, F. Zettl, K. Borschert, R. Lutterbuse, R. Kischel, and G. Riethmuller Minimal costimulatory requirements for T cell priming and TH1 differentiation: Activation of naive human T lymphocytes by tumor cells armed with bifunctional antibody constructs Cancer Immun 1 2001 10
27. A. Loffler, M. Gruen, C. Wuchter, F. Schriever, P. Kufer, and T. Dreier Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct Leukemia 17 2003 900 909
28. A. Loffler, P. Kufer, R. Lutterbuse, F. Zettl, P.T. Daniel, and J.M. Schwenkenbecher A recombinant bispecific single-chain antibody, CD19 × CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes Blood 95 2000 2098 2103
29. M. Mack, G. Riethmuller, and P. Kufer A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity Proc Natl Acad Sci U S A 92 1995 7021 7025
30. B. Mlecnik, G. Bindea, F. Pages, and J. Galon Tumor immunosurveillance in human cancers Cancer Metastasis Rev 30 2011 5 12
31. M. Molhoj, S. Crommer, K. Brischwein, D. Rau, M. Sriskandarajah, and P. Hoffmann CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis Mol Immunol 44 2007 1935 1943
32. D. Nagorsen, and P.A. Baeuerle Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab Exp Cell Res 317 2011 1255 1260
33. D. Nagorsen, R. Bargou, D. Ruttinger, P. Kufer, P.A. Baeuerle, and G. Zugmaier Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab Leuk Lymphoma 50 2009 886 891
34. A. Pezzutto, B. Dörken, P.S. Rabinovitch, J.A. Ledbetter, G. Moldenhauer, and E.A. Clark CD19 monoclonal antibody HD37 inhibits anti-immunoglobulin-induced B cell activation and proliferation J Immunol 138 1987 2793 2799
35. D.L. Porter, B.L. Levine, M. Kalos, A. Bagg, and C.H. June Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia N Engl J Med 365 2011 725 733
36. G.A. Rabinovich, D. Gabrilovich, and E.M. Sotomayor Immunosuppressive strategies that are mediated by tumor cells Annu Rev Immunol 25 2007 267 296
37. T. Raff, N. Gokbuget, S. Luschen, R. Reutzel, M. Ritgen, and S. Irmer Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: Data from the GMALL 06/99 and 07/03 trials Blood 109 2007 910 915
38. E. Ramsdale, K. van Besien, and S.M. Smith Personalized treatment of lymphoma: Promise and reality Semin Oncol 38 2011 225 235
39. S. Raponi, M.S. De Propris, S. Intoppa, M.L. Milani, A. Vitale, and L. Elia Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: Analysis of 552 cases Leuk Lymphoma 52 2011 1098 1107
40. R.C. Rickert, K. Rajewsky, and J. Roes Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice Nature 376 1995 352 355
41. I. Rousalova, and E. Krepela Granzyme B-induced apoptosis in cancer cells and its regulation (review) Int J Oncol 37 2010 1361 1378
42. B. Schlereth, C. Quadt, T. Dreier, P. Kufer, G. Lorenczewski, and N. Prang T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct Cancer Immunol Immunother 55 2006 503 514
43. T. Sousou, and J. Friedberg Rituximab in indolent lymphomas Semin Hematol 47 2010 133 142
44. J.B. Swann, and M.J. Smyth Immune surveillance of tumors J Clin Invest 117 2007 1137 1146
45. M.S. Topp, N. Goekbuget, G. Zugmaier, A. Viardot, M. Stelljes, and S. Neumann Anti-CD19 BiTE blinatumomab induces high complete remission rate in adult patients with relapsed B-precursor ALL: Updated results of an ongoing phase II trial Blood (ASH Annual Meeting Abstracts) 118 2011 21, 252
46. M.S. Topp, P. Kufer, N. Gokbuget, M. Goebeler, M. Klinger, and S. Neumann Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival J Clin Oncol 29 2011 2493 2498
47. A. Viardot, M. Goebeler, R. Noppeney, S.W. Krause, S. Kallert, and B. Ferstl Blinatumomab monotherapy shows efficacy in patients with relapsed diffuse large B cell lymphoma Blood (ASH Annual Meeting Abstracts) 118 2011 21, 1637
48. + T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma Clin Cancer Res 13 2007 388 397
49. J. Weber Ipilimumab: Controversies in its development, utility and autoimmune adverse events Cancer Immunol Immunother 58 2009 823 830
50. + in B-lineage childhood acute lymphoblastic leukemia Haematologica 95 2010 679 683
51. L. Zhang, J.R. Conejo-Garcia, D. Katsaros, P.A. Gimotty, M. Massobrio, and G. Regnani Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer N Engl J Med 348 2003 203 213